Healthcare Industry News: MEVION S250
News Release - April 14, 2014
Mevion Medical Systems Announces An Exclusive Partnership with Chiyoda Technol Corporation for Distribution of the MEVION S250 Proton Therapy System in JapanLITTLETON, Mass.--(Healthcare Sales & Marketing Network)--Mevion Medical Systems is pleased to announce an agreement with Chiyoda Technol Corporation for the exclusive distribution of the MEVION S250 Proton Therapy System in the Japanese market. Chiyoda Technol is one of Japan’s leading providers of radiation supply, service and monitoring.
The MEVION S250 proton therapy system is a unique proton therapy platform – a single-room, gantry-mounted proton accelerator that frees hospitals and private treatment facilities from the astronomical costs, prohibitive space requirements and cumbersome workflow that to date have defined this effective treatment modality.
“The significantly reduced size and cost of the MEVION S250, paired with cutting-edge technology is a perfect fit for the very progressive Japanese radiation therapy market”, said Kazuhiko Yamaguchi, President of Chiyoda Technol Corporation. “We have a strong tradition of introducing state-of-the-art medical products and with the addition of the MEVION S250 Proton Therapy System, we are fulfilling the demand of our foremost customers and we expect to significantly increase the number of proton therapy centers in the next 5 years.”
“Mevion is proud to expand its partnership with Chiyoda Technol to provide this revolutionary proton therapy platform to clinicians and patients in Japan”, said Joseph K. Jachinowski, Chief Executive Officer of Mevion. “With Japan’s 20 year leadership in the clinical use of proton therapy, the Japanese market has always been a high priority and we are excited to see the very positive response the MEVION S250 is receiving from all proton experts”. Mevion’s Asian headquarters in Tokyo supports the marketing, sales, installation and service of the MEVION S250 for Japan, as well as partnerships in Korea, Taiwan, and Thailand.
The MEVION S250 is installed at the Kling Proton Therapy Center at Barnes-Jewish Hospital at Washington University in St. Louis, MO, benefiting pediatric patients and other cancer patients where proton therapy treatment is indicated. Five additional MEVION S250 proton therapy systems are under installation at Robert Wood Johnson University Hospital in New Brunswick, N.J.; Stephenson Cancer Center at the University of Oklahoma in Oklahoma City, Okla.; First Coast Oncology in Jacksonville, Fla.; University of Florida Health Cancer Center at Orlando Health; and University Hospitals Seidman Cancer Center in Cleveland, Ohio, making Mevion Medical Systems a leading supplier of proton therapy in the U.S.
About Mevion Medical Systems
Mevion Medical Systems, Inc. is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality.
Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.
Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.
Visit us at: http://www.mevion.com.
Source: Mevion Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.